Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Culture Biosciences Appoints Chris Williams as Chief Executive Officer
Posted: September 27, 2024 at 2:51 am
Former COO of Cytek Biosciences brings extensive bioprocessing experience to drive next phase of growth at Culture Biosciences Former COO of Cytek Biosciences brings extensive bioprocessing experience to drive next phase of growth at Culture Biosciences
Follow this link:
Culture Biosciences Appoints Chris Williams as Chief Executive Officer
Posted in Global News Feed
Comments Off on Culture Biosciences Appoints Chris Williams as Chief Executive Officer
Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome
Posted: September 27, 2024 at 2:51 am
MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria
Read the original post:
Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome
Posted in Global News Feed
Comments Off on Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
Posted: September 27, 2024 at 2:51 am
REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Biomea’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.
See more here:
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
Posted in Global News Feed
Comments Off on FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Posted: September 27, 2024 at 2:51 am
Company Announcement
Continue reading here:
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Posted in Global News Feed
Comments Off on Grant of Restricted Stock Units and Warrants to Employees in Genmab
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
Posted: September 27, 2024 at 2:51 am
CAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that its stockholders voted to approve the previously announced proposed sale of the Company’s VOWST business to Société des Produits Nestlé S.A. Seres will file a Current Report on Form 8-K with the SEC which details the voting results. The transaction is expected to close on September 30, 2024, subject to the satisfaction of customary closing conditions.
Here is the original post:
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
Posted in Global News Feed
Comments Off on Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing…
Posted: September 27, 2024 at 2:51 am
Company to host conference call today at 4:30 p.m. ET Company to host conference call today at 4:30 p.m. ET
See original here:
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing...
Posted in Global News Feed
Comments Off on Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing…
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
Posted: September 27, 2024 at 2:51 am
TORONTO and HAIFA, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, is pleased to announce a non-brokered private placement of up to 3,636,363 units (“Units”) at a price of $0.55 per Unit for aggregate gross proceeds of up to $2,000,000 (the “Offering”) and will, on acceptance of the TSX Venture Exchange (“TSXV”), close on a first tranche of the Offering for gross proceeds of $1,610,147.55. The Company intends to use the proceeds of the Offering for working capital purposes.
Here is the original post:
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
Posted in Global News Feed
Comments Off on NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays
Posted: September 27, 2024 at 2:51 am
Product line earns CE-marking under new EU IVDR framework – including QIAstat-Dx Analyzer, QIAstat-Dx Rise and panels for detection of gastrointestinal and respiratory infections // Certification confirms that QIAGEN’s devices meet the stringent safety, quality and performance standards for in-vitro diagnostics in Europe // QIAGEN on track to transition over 180 products to new IVDR regulatory framework Product line earns CE-marking under new EU IVDR framework – including QIAstat-Dx Analyzer, QIAstat-Dx Rise and panels for detection of gastrointestinal and respiratory infections // Certification confirms that QIAGEN’s devices meet the stringent safety, quality and performance standards for in-vitro diagnostics in Europe // QIAGEN on track to transition over 180 products to new IVDR regulatory framework
Go here to see the original:
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays
Posted in Global News Feed
Comments Off on QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
Posted: September 27, 2024 at 2:51 am
New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert
The rest is here:
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
Posted in Global News Feed
Comments Off on Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
Posted: September 27, 2024 at 2:51 am
TARRYTOWN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2024 financial and operating results on Thursday, October 31, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Go here to read the rest:
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
Posted in Global News Feed
Comments Off on Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
